Is Royalty Pharma PLC (RPRX) a risky stock?
As of July 23, 2026, Clavix grades Royalty Pharma PLC (RPRX) A for risk, a composite score of 87 out of 100 on an A+ to F scale, which puts RPRX in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 23, 2026. Clavix regrades every trading day.
The five risk dimensions behind RPRX's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how RPRX scores on each, as of July 23, 2026.
What's moving RPRX's risk right now
Company-specific signals Clavix flags behind RPRX's current grade, drawn from recent news and filings as of July 23, 2026.
RPRX is deploying meaningful capital into a late-stage, Phase 3 cardiovascular asset with large market potential, which could create upside if cliramitug secures FDA approval but…
Investors may expect RPRX to deliver above-consensus earnings in its upcoming quarter, potentially supporting positive near-term price action.
The deal expands RPRX's royalty portfolio with a late-stage AstraZeneca asset, deploying meaningful capital upfront while tying remaining $300M to potential milestones, which coul…
Recent RPRX news
The latest headlines Clavix ingested for Royalty Pharma PLC, newest first. These feed the news-sentiment dimension of RPRX's grade.
-
Royalty Pharma agreed to pay $125 million upfront (part of a $425 million deal) to Neurimmune for a royalty stake in AstraZeneca's transthyretin-mediated amyloidosis (ATTR) drug. This marks RPRX's second royalty deal in the ATTR space.
-
Royalty Pharma (RPRX) is acquiring a 3%-4% royalty interest in AstraZeneca's Phase 3 ATTR-CM drug cliramitug from Neurimmune for up to $425 million, consisting of a $125 million upfront payment plus additional milestone-based payments.
-
Royalty Pharma (RPRX) acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront.
What a A grade means
On the Clavix A+ to F scale, RPRX's composite of 87 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell RPRX or any security. Grades are risk indicators, not predictions of return. Data may be delayed.